{"entity":{"id":"jesus-berdeja","kind":"person","name":"Jesús G. Berdeja","aka":[],"tldr":"Led CARTITUDE-1, the trial that brought ciltacabtagene autoleucel, the most active myeloma CAR-T, to approval.","summary":"Jesús Berdeja (Sarah Cannon Research Institute, Nashville) was principal investigator and first author of CARTITUDE-1, the pivotal trial showing the BCMA CAR-T ciltacabtagene autoleucel produces responses in 98% of heavily pretreated myeloma patients with median progression-free survival near three years, the deepest responses seen in relapsed myeloma. He runs a large community-based early-phase programme.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Berdeja%20JG%5BAuthor%5D%20ciltacabtagene"}],"tags":["myeloma","car-t","community-research"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":["car-t"],"targets":["bcma"],"drugs":["ciltacabtagene-autoleucel"],"companies":[],"institutions":["tennessee-oncology"],"pathways":[],"terms":[],"trials":["cartitude-1"],"people":[],"bottlenecks":[],"keyPapers":["paper-cartitude-1-cilta-cel-lancet-2021"],"journals":[],"dependsOn":[],"notes":[],"role":"Director of Myeloma Research, Greco-Hainsworth Centers for Research, Tennessee Oncology; Sarah Cannon Research Institute","institutionId":"tennessee-oncology","specialisms":["Multiple myeloma","CAR T-cell therapy","Early drug development","Community-based trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Berdeja%20JG%5BAuthor%5D%20ciltacabtagene"}],"papers":[{"title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study","journal":"Lancet","year":2021,"doi":"10.1016/S0140-6736(21)00933-8"},{"title":"Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 final results","journal":"JCO","year":2025},{"title":"CARTITUDE-1: cilta-cel, a BCMA CAR-T, in heavily pretreated myeloma","journal":"The Lancet","year":2021,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CARTITUDE-1%20ciltacabtagene%20autoleucel%20Berdeja%20Lancet%202021"}]},"route":"/people/jesus-berdeja/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/"}],"drug":[{"id":"ciltacabtagene-autoleucel","kind":"drug","name":"Ciltacabtagene autoleucel","route":"/drugs/ciltacabtagene-autoleucel/"}],"institution":[{"id":"tennessee-oncology","kind":"institution","name":"Tennessee Oncology / Greco-Hainsworth Centers for Research","route":"/institutions/tennessee-oncology/"}],"trial":[{"id":"cartitude-1","kind":"trial","name":"CARTITUDE-1","route":"/trials/cartitude-1/"}],"paper":[{"id":"paper-cartitude-1-cilta-cel-lancet-2021","kind":"paper","name":"CARTITUDE-1: cilta-cel, a BCMA CAR-T, in heavily pretreated myeloma","route":"/key-papers/paper-cartitude-1-cilta-cel-lancet-2021/"}]}}